← Back to patent-cliff list
Petadeferitrin
Tier C — Watch / tradePetadeferitrin
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Beta thalassaemia, Myelodysplastic syndrome, Iron overload
Regional status
US
Discontinued
2014-10-01
EU
Phase II
2023-09-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Petadeferitrin?
Approved indications include: Beta thalassaemia, Myelodysplastic syndrome, Iron overload.
When does the Petadeferitrin patent expire?
No public expiry year is available for Petadeferitrin yet; this page updates once verified.
How do I get a quote for Petadeferitrin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06